AmbroseNMorganTAGallowayJet al.Differences in disease phenotype and severity in SLE across age groups. Lupus2016; 25: 1542–1550.
2.
MahmoudIJellouliMBoukhrisIet al.Efficacy and safety of rituximab in the management of pediatric systemic lupus erythematosus: A systematic review. J Pediatr2017; 187: 213–219.e2.
3.
WatsonLBeresfordMWMaynesCet al.The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus2015; 24: 10–17.
4.
WangNShenNVyseTJet al.Selective IgA deficiency in autoimmune diseases. Mol Med Camb Mass2011; 17: 1383–1396.
5.
AnolikJHBarnardJOwenTet al.Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum2007; 56: 3044–3056.
6.
DiasSSRodriguez-GarciaVNguyenHPericleousCIsenbergD. Longer duration of B cell depletion is associated with better outcome. Rheumatology (Oxford)2015; 54: 1876–1881.
7.
KlepfishARachmilewitzEAKotsianidisIPatchenkoPSchattnerA. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM2008; 101: 737–740.
8.
Md YusofMYShawDEl-SherbinyYMet al.Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis2017; 76: 1829–1836.
